Pierre Luzeau on Seqens U.S. R&D Lab Investment
The merger creates a scaled leader of global industrial footprint and further extends both companies’ broad portfolio of products, services and advanced pharmaceutical technologies, while maintaining their strong culture of quality, regulatory compliance and commitment for exceptional customer service.
SK Capital Partners has entered into exclusive discussions to acquire a majority stake in SEQENS – a leading integrated developer and manufacturer of Active Pharmaceutical Ingredients, advanced drug intermediates and specialty ingredients.
Wavelength Pharmaceuticals signs collaboration agreement with Tikun olam-Cannbit for development, manufacturing and marketing of Pharma Grade cGMP cannabis-based active pharmaceutical ingredients (APIs).
Biocatalytic processing offers a wealth of advantages and should be evaluated during early-stage drug development.
As the Covid-19 pandemic continues to challenge the global drug supply chain, nations are looking for new ways to enable native producers to continue scaling up. Now, an Israeli API maker is dropping a down payment into an Indian intermediates company to ramp up its own manufacturing base.
Clinical Ink, a global clinical trial technology company, has announced a wide-ranging Study Assurance Program to minimize financial impact of the disruption from COVID-19 on new and existing clinical trials. The effect of global quarantines has dramatically impacted new patient recruitment and has substantially changed how existing patients participate in ongoing clinical trials.
PETAH TIKVAH, Israel--(BUSINESS WIRE)--Wavelength Pharmaceuticals, a leading developer and manufacturer of active pharmaceutical ingredients (APIs), today announced the acquisition of a majority stake in Vanamali Organics Pvt. Ltd. of Telangana, India.
HPAPI Complexity Prompts New Delivery Mechanisms
The COVID-19 pandemic has forced many pharmaceutical companies to dramatically increase production of essential drugs needed to manage respiratory critical care patients who are ventilated as an important part of their treatment. In turn, this has placed an unprecedented demand on those manufacturing active pharmaceutical ingredients (APIs), highlighting the importance of adaptability in order to maintain supply. Not only must API manufacturers have robust processes in place to enable rapid scale up, but they must also implement measures that address the global interdependency of pharmaceutical supply chains to avoid unnecessary production delays.